rabbit anti-cd4 mab  (Servicebio Inc)

Journal: Antibody Therapeutics

Article Title: Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo

doi: 10.1093/abt/tbaf008

Figure Lengend Snippet: (A) Representative whole-body, ventral bioluminescence imaging of mice implanted with human lymphoma Raji cells expressing the reporter firefly luciferase. On day 14 after the start of treatment, tumor lesions in NAV-006-treated mice (bottom panel) are undetectable, whereas they are visible in vehicle-treated mice (top panel). Smaller lesions are detectable in some of the mice treated with rituximab (center panel). (B-C) independent studies using the same model as in (A); in both examples, the results show statistically significant antitumor activity mediated by NAV-006, while rituximab effect fails to achieve statistical significance. (D) Data from studies in (B) and (C) were pooled and statistical analysis is presented in a combined chart. One-way ANOVA with Dunnett’s multiple comparison test; ns = not statistically significant; * = P < 0.05. (E) Immunohistochemistry analysis for detection of CD4-positive human lymphocytes. Spleen tissues harvested from five representative mice 28 days after the start of treatment were probed with an anti-human CD4 antibody as described in materials and methods. Three of five animals had spleens colonized by human lymphocytes even 4 weeks after PBMCs transfer. Scale bar: 200 µm.

Article Snippet: To confirm engraftment of human PBMCs in mice, we employed immunohistochemistry (IHC) using a rabbit anti-human CD4 antibody (10400-R113, Sino Biological).

Techniques: Imaging, Expressing, Luciferase, Activity Assay, Comparison, Immunohistochemistry

Journal: Scientific Reports

Article Title: GliaTrap is a biodegradable, non-swelling and non-inflammatory hydrogel with tuned release of CXCL12 to attract migrating glioblastoma cells

doi: 10.1038/s41598-025-02977-x

Figure Lengend Snippet: GliaTrap does not induce inflammatory infiltration in vivo. Mouse brain coronal Sect. (4 μm thickness) at the level of injection site across three experimental groups: subhippocampal needle stick only ( A – E ), injection of hydrogel vehicle only ( F – J ), and injection of hydrogel containing CXCL12 (GliaTrap) ( K – O ). Representative images are shown, chosen from among n = 3 mice in each experimental group. From left to right, slices were prepared with H&E staining; F4/80 mAb 1:250 to identify macrophages; CD4 mAb 1:100 to identify CD4 + T-Cells; CD8a mAb 1:400 to identify CD8 + T-Cells; and Granzyme B mAb 1:100 to identify activated T cells and natural killer cells. All antibodies and concentrations were the same as for spleen positive control staining from the injection-only mice, as shown in (Supplementary Fig. ). Antibody positivity was observed in F4/80 in all three groups adjacent to the injection site (purple arrows), but not in slices prepared using the other three antibodies. Images were captured using an Axio Observer Z1/7 microscope, Axiocam 705 1X Camera Adapter, and EC Plan-Neuofluar 10X / 0.30 M27 Objective.

Article Snippet: Mouse brain and spleen coronal Sect. (4 μm thickness) were prepared with H&E staining; F4/80 mAb (Cell Signaling Technologies, Rabbit mAb #70076) 1:250 to identify macrophages; CD4 mAb (Cell Signaling Technologies, Rabbit mAb #25229) 1:100 to identify CD4 + T-Cells; CD8a mAb (Cell Signaling Technologies, Rabbit mAb # 98941) 1:400 to identify CD8 + T-Cells; and Granzyme B mAb (Cell Signaling Technologies, Rabbit mAb # 44153) 1:100 to identify activated T cells and natural killer cells.

Techniques: In Vivo, Injection, Staining, Positive Control, Microscopy